A5090256464- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Occupational and environmental lung diseases
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Pleural and Pulmonary Diseases
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Bone health and treatments
- Medical Imaging and Pathology Studies
- Neuroblastoma Research and Treatments
- Advances in Oncology and Radiotherapy
- Radiopharmaceutical Chemistry and Applications
University of Pennsylvania
2015-2024
University of Pennsylvania Health System
2014-2024
Abramson Cancer Center
2010-2024
Penn Center for AIDS Research
2024
Hospital of the University of Pennsylvania
2012-2023
Fox Chase Cancer Center
2006-2023
Baylor University Medical Center
2004-2023
University of California, San Francisco
2004-2023
Philadelphia University
2010-2022
California University of Pennsylvania
2009-2021
We conducted a randomized study to determine whether any of three chemotherapy regimens was superior cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer.
To investigate the efficacy and safety of bevacizumab plus carboplatin paclitaxel in patients with advanced or recurrent non-small-cell lung cancer.
The combination of chemotherapy with thoracic radiotherapy (TRT) compared TRT alone has been shown to confer a survival advantage for good performance status patients stage III non–small cell lung cancer. However, it is not known whether sequential or concurrent delivery these therapies the optimal strategy. A total 610 were randomly assigned two regimens and one regimen in three-arm phase trial. arm included cisplatin at 100 mg/m 2 on days 1 29 vinblastine 5 per week weeks 60 Gy beginning...
Survival has decreased among patients with laryngeal cancer during the past 2 decades in United States. During this same period, there been an increase nonsurgical treatment of cancer.The objectives study were to identify trends demographics, management, and outcome States analyze factors contributing survival.The authors conducted a retrospective, longitudinal cases.Review National Cancer Data Base (NCDB) revealed 158,426 cases squamous cell carcinoma (excluding verrucous carcinoma)...
Purpose Etoposide and cisplatin (EP) has been a standard treatment for extensive-disease small-cell lung cancer (SCLC). An earlier phase III trial reported improved survival patients receiving irinotecan plus (IP) versus EP. Our was designed to determine if modified weekly regimen of IP would provide superior with less toxicity than Patients Methods The primary objective compare overall in SCLC randomly assigned receive (n = 221) or EP 110). were 2:1 ratio 30 mg/m 2 intravenously (IV) + 65...
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods were stratified by brain metastases best response to crizotinib. They randomly assigned (1:1) oral brigatinib 90 mg once daily (arm A) or 180 a 7-day...
Background: Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy. We performed a retrospective analysis Eastern Cooperative Oncology Group (ECOG) 5592, phase III randomized trial chemotherapy regimens for non-small-cell lung cancer (NSCLC), and compared outcomes in enrollees 70 years age older with those younger patients. Methods: ECOG carried out cisplatin plus either etoposide or paclitaxel chemotherapy-naïve NSCLC patients stages IIIB...
Irinotecan plus cisplatin (IP) improved survival over etoposide (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) outcomes, we conducted a large randomized trial identical design to North American E-SCLC.Patients were randomly assigned IP (irinotecan 60 mg/m(2) on days 1, 8, 15; day every 4 weeks) or EP (etoposide 100 1 through 3; 80 3 weeks). Blood specimens for...
Abstract Background We sought to examine the current state of cancer care for head and neck tumors in United States. therefore performed a retrospective, longitudinal study approximately 822,000 cases included National Cancer Data Base (NCDB) 1990 through 2004, representing 75% estimated incident diagnoses Methods All diagnosed reported NCDB during this interval were reviewed, descriptive statistics, grouped by disease host factors, analyzed over time compared with prior similar analysis...
The clinical implications of adding plasma-based circulating tumor DNA next-generation sequencing (NGS) to tissue NGS for targetable mutation detection in non-small cell lung cancer (NSCLC) have not been formally assessed.To determine whether plasma testing was associated with improved and enhanced delivery personalized therapy a real-world setting.This prospective cohort study enrolled 323 patients metastatic NSCLC who had ordered as part routine management. Plasma performed using 73-gene...
Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology SCLC focus on extensive-stage because it occurs more frequently than limited-stage disease. is highly sensitive to initial therapy; however, patients eventually die recurrent In with disease, chemotherapy alone can palliate symptoms and prolong survival patients; long-term rare. Most cases attributable cigarette smoking; therefore,...
Recurrent squamous cell carcinoma of the head and neck (SCCHN) or new second primary tumor (SPT) in a previous radiation field, if not curable by surgery radiation, is almost always fatal. Chemotherapy alone yields median survival time (MST) no more than 10 months 1-year overall (OS) 35% at best. Concurrent reirradiation chemotherapy an alternative strategy.Eligibility for Radiation Therapy Oncology Group (RTOG) protocol 9911 stipulated recurrent SCCHN SPT field. Patients received...
Fit elderly patients with advanced non-small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination carboplatin (C) and paclitaxel (P) improves survival for advanced, nonsquamous NSCLC, as evidenced Eastern Cooperative Oncology Group (ECOG) 4599. We conducted a subset analysis of ECOG 4599 to determine the outcome patients.ECOG randomly assigned NSCLC PC or PCB. analyzed who were at least 70 years age time study entry. Patient...
The expanding number of targeted therapeutics for non-small cell lung cancer (NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform serially and often yield inadequate DNA next-generation sequencing (NGS). We evaluated the feasibility using cell-free circulating (ctDNA) NGS as a complement or alternative NGS.A total 112 plasma samples obtained from consecutive study 102 prospectively enrolled patients with advanced NSCLC were subjected ultra-deep up 70...
Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for use immunotherapy exists in minimal residual disease state.To evaluate whether addition pembrolizumab after LAT improves outcomes patients NSCLC.This single-arm phase 2 trial was performed February 1, 2015, through September 30, 2017,...
IntroductionThis exploratory analysis retrospectively evaluated outcomes in patients with advanced NSCLC to determine whether baseline brain metastases influenced the efficacy of first-line pembrolizumab plus chemotherapy versus alone.MethodsWe pooled data for KEYNOTE-021 cohort G (nonsquamous), KEYNOTE-189 and KEYNOTE-407 (squamous). Patients were assigned platinum-doublet or without addition 35 cycles 200 mg every 3 weeks. All studies permitted enrollment previously treated untreated...